CompletedPhase 2NCT03698864
A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
Studying Necrobiosis lipoidica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Processa Pharmaceuticals
- Principal Investigator
- Maya Das, MD, M.DProcessa Pharmaceuticals
- Intervention
- PCS499(drug)
- Enrollment
- 12 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2018 – 2020
Study locations (2)
- Processa Investigational Site, Philadelphia, Pennsylvania, United States
- Processa Investigational Site, Pittsburgh, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03698864 on ClinicalTrials.gov